Anne Schuchat, a spokeswoman for U.S. Centers for Disease Control and Prevention, has announced that the first human H1N1 vaccine to be delivered to U.S residents will be 600,000 doses of a nasal spray made by MedImmune, a division of AstraZeneca, according to Reuters.
The vaccine will begin arriving in states and cities next week, U.S. health officials said on Thursday. "This is a bit earlier than we were planning to get started," according to Schuchat.
The nasal spray is approved for people aged 2 to 49 who do not have asthma, but Schuchat said plenty of people could benefit from it anyway. The CDC is ordering flu vaccine from five makers and expects to get between 6 million and 7 million doses to its central U.S. distributor next week.
Schuchat says H1N1 pandemic flu was now widespread across the United States. "What we are seeing is quite striking," she said. While H1N1 is causing more severe disease among younger people than seasonal flu, it is no deadlier.